Research Analysts Issue Forecasts for ACRS FY2029 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Investment analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of Aclaris Therapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the biotechnology company will post earnings per share of ($1.02) for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.86) per share.

Several other equities analysts have also issued reports on ACRS. StockNews.com lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Leerink Partners raised Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the company from $2.00 to $7.00 in a research report on Tuesday, November 19th. Jefferies Financial Group raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the stock from $2.00 to $7.00 in a report on Tuesday, November 19th. Cantor Fitzgerald upgraded shares of Aclaris Therapeutics to a “strong-buy” rating in a report on Thursday, January 30th. Finally, BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 target price for the company in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $11.00.

Aclaris Therapeutics Stock Performance

NASDAQ:ACRS opened at $2.49 on Thursday. Aclaris Therapeutics has a 52 week low of $0.95 and a 52 week high of $5.17. The firm has a 50-day moving average price of $2.85 and a two-hundred day moving average price of $2.05. The firm has a market cap of $177.86 million, a price-to-earnings ratio of -4.79 and a beta of 0.50.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. The firm had revenue of $4.35 million for the quarter, compared to the consensus estimate of $8.31 million.

Insider Transactions at Aclaris Therapeutics

In other Aclaris Therapeutics news, Director Anand Mehra acquired 666,666 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average cost of $2.25 per share, with a total value of $1,499,998.50. Following the acquisition, the director now owns 710,030 shares in the company, valued at approximately $1,597,567.50. This represents a 1,537.37 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Aclaris Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. bought a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at $82,000. Assenagon Asset Management S.A. purchased a new position in Aclaris Therapeutics during the 3rd quarter valued at about $214,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Aclaris Therapeutics by 187.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock valued at $382,000 after buying an additional 216,826 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Aclaris Therapeutics in the fourth quarter worth about $383,000. Finally, Geode Capital Management LLC boosted its position in shares of Aclaris Therapeutics by 9.3% in the third quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock valued at $974,000 after acquiring an additional 72,309 shares during the period. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.